Report from Annual General Meeting of Vitrolife AB (publ)
Vitrolife held its Annual General Meeting, approving several key decisions for 2025. Shareholders approved a dividend of SEK 1.10 per share for 2024, with May 2, 2025, set as the record date.
The board saw the re-election of five members, with Jón Sigurdsson appointed as Chairman. Total board remuneration increased to SEK 3.67 million, up from SEK 3.3 million. Deloitte AB was re-elected as auditor.
Key authorizations granted include:
- Permission to issue up to 13,544,719 shares (10% of share capital)
- Authority to acquire company shares (max 10% of total shares)
- Implementation of a share-based incentive program with 480,000 warrants
The meeting also approved new guidelines for executive management compensation.
Vitrolife ha tenuto l'Assemblea Generale Annuale, approvando diverse decisioni chiave per il 2025. Gli azionisti hanno approvato un dividendo di 1,10 SEK per azione per il 2024, con il 2 maggio 2025 come data di riferimento.
Il consiglio ha visto la rielezione di cinque membri, con Jón Sigurdsson nominato Presidente. La remunerazione totale del consiglio è aumentata a 3,67 milioni di SEK, rispetto ai 3,3 milioni precedenti. Deloitte AB è stata rieletta come revisore dei conti.
Le principali autorizzazioni concesse includono:
- Permesso di emettere fino a 13.544.719 azioni (10% del capitale sociale)
- Autorizzazione ad acquisire azioni della società (max 10% del totale azioni)
- Implementazione di un programma incentivante basato su azioni con 480.000 warrant
L'assemblea ha inoltre approvato nuove linee guida per la remunerazione del management esecutivo.
Vitrolife celebró su Junta General Anual, aprobando varias decisiones clave para 2025. Los accionistas aprobaron un dividendo de 1,10 SEK por acción para 2024, con fecha de registro el 2 de mayo de 2025.
Se reelegieron cinco miembros del consejo, y Jón Sigurdsson fue nombrado Presidente. La remuneración total del consejo aumentó a 3,67 millones de SEK, desde 3,3 millones. Deloitte AB fue reelegida como auditor.
Las autorizaciones clave otorgadas incluyen:
- Permiso para emitir hasta 13.544.719 acciones (10% del capital social)
- Facultad para adquirir acciones de la empresa (máximo 10% del total de acciones)
- Implementación de un programa de incentivos basado en acciones con 480.000 warrants
La junta también aprobó nuevas directrices para la compensación de la alta dirección.
Vitrolife는 2025년을 위한 여러 주요 결정을 승인하며 연례 주주총회를 개최했습니다. 주주들은 2024년 배당금으로 주당 SEK 1.10을 승인했으며, 기준일은 2025년 5월 2일로 정해졌습니다.
이사회는 다섯 명의 이사 재선임과 함께 Jón Sigurdsson을 의장으로 선임했습니다. 이사회 총 보수는 SEK 3.3백만에서 SEK 3.67백만으로 증가했습니다. Deloitte AB가 감사로 재선임되었습니다.
주요 승인 권한은 다음과 같습니다:
- 최대 13,544,719주(자본금의 10%)까지 신주 발행 허가
- 회사 주식 최대 10%까지 취득 권한
- 480,000 워런트를 포함한 주식 기반 인센티브 프로그램 시행
총회는 또한 경영진 보상에 대한 새로운 지침을 승인했습니다.
Vitrolife a tenu son Assemblée Générale Annuelle, approuvant plusieurs décisions clés pour 2025. Les actionnaires ont approuvé un dividende de 1,10 SEK par action pour 2024, la date de référence étant fixée au 2 mai 2025.
Cinq membres du conseil ont été réélus, avec Jón Sigurdsson nommé Président. La rémunération totale du conseil a augmenté à 3,67 millions de SEK, contre 3,3 millions auparavant. Deloitte AB a été réélu en tant qu’auditeur.
Les principales autorisations accordées comprennent :
- Permission d’émettre jusqu’à 13 544 719 actions (10 % du capital social)
- Autorisation d’acquérir des actions de la société (maximum 10 % du total des actions)
- Mise en place d’un programme d’incitation basé sur des actions avec 480 000 bons de souscription
L’assemblée a également approuvé de nouvelles directives pour la rémunération de la direction exécutive.
Vitrolife hielt seine Jahreshauptversammlung ab und genehmigte mehrere wichtige Entscheidungen für 2025. Die Aktionäre stimmten einer Dividende von 1,10 SEK pro Aktie für 2024 zu, mit dem 2. Mai 2025 als Stichtag.
Der Vorstand wurde mit fünf Mitgliedern wiedergewählt, und Jón Sigurdsson wurde zum Vorsitzenden ernannt. Die Gesamtvergütung des Vorstands stieg auf 3,67 Millionen SEK von zuvor 3,3 Millionen. Deloitte AB wurde als Abschlussprüfer wiedergewählt.
Wichtige erteilte Genehmigungen umfassen:
- Erlaubnis zur Ausgabe von bis zu 13.544.719 Aktien (10 % des Grundkapitals)
- Ermächtigung zum Erwerb von Gesellschaftsanteilen (max. 10 % der Gesamtaktien)
- Einführung eines aktienbasierten Anreizprogramms mit 480.000 Optionsscheinen
Die Versammlung genehmigte außerdem neue Richtlinien für die Vergütung der Geschäftsleitung.
- Dividend payment of SEK 1.10 per share approved for 2024
- Board authorization to issue up to 13.5M new shares (10% of capital) for potential growth opportunities
- Implementation of share-based incentive program to align management interests with shareholders
- Board remuneration increased by 11.2% to SEK 3.67M from SEK 3.3M
- Potential share dilution risk up to 10% from new share issuance authorization
- Additional dilution possible from 480,000 warrants issued for incentive program
- Resolution in accordance with the Board's proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
- Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.
- Remuneration to the Board members is proposed to be in total
SEK 3 670 000 (3 300 000) of whichSEK 1 350 000 (1 200 000) to the Chairman of the Board,SEK 450 000 (400 000) to each of the other members of the Board,SEK 160 000 (150 000) to the Chairman of the Audit Committee andSEK 80 000 (75 000) to each of the other members of the Audit Committee. - Re-election of Deloitte AB as auditor with unchanged remuneration principles.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
- The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
- Implementation of a share-based incentive program including issue of a maximum number of 480,000 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities.
VITROLIFE AB (publ)
The Board
The information was submitted for publication, through the agency of the contact persons set out above, at 30-04-2025 09:08 CET.
Contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Report from Annual General Meeting of Vitrolife AB (publ) |
View original content:https://www.prnewswire.com/news-releases/report-from-annual-general-meeting-of-vitrolife-ab-publ-302442384.html
SOURCE Vitrolife AB (publ)
FAQ
What dividend did Vitrolife (VTRLY) announce for 2024?
How many shares can Vitrolife (VTRLY) issue under the new authorization in 2025?
What is the new Board compensation structure for Vitrolife (VTRLY) in 2025?
How many warrants did Vitrolife (VTRLY) approve in their 2025 incentive program?
What share buyback authorization was approved at Vitrolife's 2025 AGM?
